NIPT is an advanced and non-invasive genetic screening test that is done from the 10th week onwards of gestation to assess the risk of certain chromosomal abnormalities in the developing foetus. The test is also known as cell-free DNA testing or cfDNA testing.

During the test, about 10 ml of maternal whole blood is taken. The circulating cell-free fetal DNA in the maternal blood is then extracted to be sequenced utilizing the NGS (Next generation sequencing) technology.

Genes2Me’s LeoNext CfDNA Library Preparation Kit for NIPT is used for detection of common trisomies using next generation sequencing.

Panoramic view of the Fetal Genome

Enhanced Test Performance

Rapid TAT

Extensively Validated on Clinical Samples

End-to-end solution

• Sample - 10 ml of EDTA Whole blood
• Disorders Tested - Trisomies 13, 18 , 21, Aneuploidies in all 22 pairs of autosomes and sex chromosome aneuploidies
• Methodology - Low-depth whole-genome sequencing
• Number of Reads - 15 – 20 Million

• Trisomy 21 (Down Syndrome)
• Trisomy 18 (Edwards’ Syndrome)
• Trisomy 13 (Patau syndrome)
• Turner Syndrome (Monosomy X/XO)

• Klinefelter Syndrome (XXY)
• Triple X (XXX)
• Jacob’s Syndrome (XYY)
• Other chromosomal aneuploidies